ATOS (Atossa Therapeutics) Shiller PE Ratio: (As of Sep. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATOS Atossa Therapeutics Inc ATOS
26 GF Score
Price $2.40
! 2 Warning Signs
View Full Analysis

What is Atossa Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Atossa Therapeutics  (NAS:ATOS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Atossa Therapeutics Shiller PE Ratio Related Terms


Atossa Therapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Atossa Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atossa Therapeutics Shiller PE Ratio Chart

Atossa Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Atossa Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ATOS vs LTRN, DYAI, PVCT: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Atossa Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atossa Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atossa Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Atossa Therapeutics's Shiller PE Ratio falls into.


ATOS
26GF Score
Atossa Therapeutics Inc ATOS
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atossa Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Atossa Therapeutics's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Atossa Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.9531/333.9520*333.9520
=-0.953

Current CPI (Jun. 2026) = 333.9520.

Atossa Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 12.600 241.428 17.429
201612 -119.954 241.432 -165.922
201703 -81.000 243.801 -110.952
201706 -115.200 244.955 -157.054
201709 -32.400 246.819 -43.838
201712 -11.273 246.524 -15.271
201803 -10.602 249.554 -14.188
201806 -76.234 251.989 -101.030
201809 -9.578 252.439 -12.671
201812 -5.332 251.233 -7.087
201903 -9.306 254.202 -12.226
201906 -11.937 256.143 -15.563
201909 -5.399 256.759 -7.022
201912 -4.301 256.974 -5.589
202003 -4.842 258.115 -6.264
202006 -6.377 257.797 -8.261
202009 -5.153 260.280 -6.611
202012 -13.280 260.474 -17.026
202103 -0.573 264.877 -0.723
202106 -0.869 271.696 -1.068
202109 -0.616 274.310 -0.750
202112 -0.572 278.802 -0.686
202203 -0.567 287.504 -0.659
202206 -0.790 296.311 -0.891
202209 -0.949 296.808 -1.068
202212 -0.887 296.797 -0.998
202303 -0.744 301.836 -0.823
202306 -1.165 305.109 -1.275
202309 -0.743 307.789 -0.806
202312 -0.928 306.746 -1.011
202403 -0.704 312.332 -0.752
202406 -0.722 314.175 -0.767
202409 -0.862 315.301 -0.913
202412 -0.752 315.605 -0.796
202503 -0.780 319.799 -0.815
202506 -0.978 322.561 -1.013
202509 -1.009 324.800 -1.038
202512 -1.270 324.054 -1.309
202603 -1.112 330.213 -1.125
202606 -0.953 333.952 -0.953

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Atossa Therapeutics Business Description

Other Exchanges ATOS:MexicoYAG:Germany
Address 1448 NW Market Street, Suite 500, Seattle, WA, USA, 98107
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
26GF Score

Get the complete analysis for ATOS

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.40
Price